Market Overview

Why MEI Pharma's Stock Is Trading Higher Today


MEI Pharma (NASDAQ: MEIP) shares are trading higher on Friday.

SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and a price target of $16 per share.

MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

MEI Pharma shares were trading up 4.85% at $3.46 at time of publication on Friday. The stock has a 52-week high of $3.82 and a 52-week low of 72 cents.

Related Links:

UK Clears Gilead's Remdesivir For Some Coronavirus Patients

10 Biopharmaceutical Companies Trying To Cure Cancer

Latest Ratings for MEIP

May 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy
Feb 2019BTIG ResearchInitiates Coverage OnBuy
Dec 2018H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for MEIP
View the Latest Analyst Ratings


Related Articles (MEIP)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

ASHEvercore ISI GroupInitiates Coverage On80.0
RPMEvercore ISI GroupInitiates Coverage On90.0
DOWEvercore ISI GroupInitiates Coverage On58.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at